$2.85 Billion is the total value of Tekla Capital Management LLC's 200 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MNKKQ | Exit | Mallinckrodt plcsponsored adr | $0 | – | -32,980 | -100.0% | -0.00% | – |
| TCDA | Exit | Tricida, Inc. | $0 | – | -50,370 | -100.0% | -0.02% | – |
| GLPG | Exit | Galapagos NVsponsored adr | $0 | – | -6,543 | -100.0% | -0.04% | – |
| GSK | Exit | GlaxoSmithKline PLCshares | $0 | – | -32,400 | -100.0% | -0.05% | – |
| BHVN | Exit | Biohaven Pharmaceutical Holding Co. Ltd. | $0 | – | -34,277 | -100.0% | -0.08% | – |
| COGT | Exit | Cogent Biosciences, Inc. | $0 | – | -1,103,175 | -100.0% | -0.10% | – |
| MYOK | Exit | MyoKardia, Inc. | $0 | – | -19,300 | -100.0% | -0.10% | – |
| BNTX | Exit | BioNTech SEsponsored ads | $0 | – | -43,595 | -100.0% | -0.11% | – |
| CHRS | Exit | Coherus Biosciences, Inc. | $0 | – | -203,103 | -100.0% | -0.14% | – |
| ACHC | Exit | Acadia Healthcare Co., Inc. | $0 | – | -131,200 | -100.0% | -0.14% | – |
| GBT | Exit | Global Blood Therapeutics, Inc. | $0 | – | -71,759 | -100.0% | -0.15% | – |
| BLUE | Exit | bluebird bio, Inc. | $0 | – | -84,194 | -100.0% | -0.17% | – |
| CERN | Exit | Cerner Corp. | $0 | – | -81,500 | -100.0% | -0.22% | – |
| AGIO | Exit | Agios Pharmaceuticals, Inc. | $0 | – | -186,964 | -100.0% | -0.24% | – |
| ABC | Exit | AmerisourceBergen Corp. | $0 | – | -80,645 | -100.0% | -0.29% | – |
| BAX | Exit | Baxter International Inc. | $0 | – | -122,023 | -100.0% | -0.37% | – |
| MYL | Exit | Mylan N.V.shares | $0 | – | -1,010,754 | -100.0% | -0.56% | – |
| IMMU | Exit | Immunomedics, Inc. | $0 | – | -223,336 | -100.0% | -0.71% | – |
| SGEN | Exit | Seagen Inc. | $0 | – | -337,204 | -100.0% | -2.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.